OncoMatch/Clinical Trials/NCT05607095
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
Is NCT05607095 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Lifileucel (LN-144/LN-145) for uveal melanoma.
Treatment: Lifileucel (LN-144/LN-145) — This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Disease stage
Required: Stage IV
metastatic Uveal Melanoma; unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
refractory to at least 1 prior line of systemic therapy
Cannot have received: organ allograft or prior cell transfer therapy that included a non-myeloablative or myeloablative chemotherapy regimen
Patients who have received an organ allograft or prior cell transfer therapy that included a non-myeloablative or myeloablative chemotherapy regimen.
Lab requirements
Blood counts
ANC ≥ 1000/mm3; Hemoglobin ≥ 9.0 g/dL; Platelet ≥ 100,000/mm3; transfusions or growth factors not allowed 28 days prior to signing ICF and through Screening
Kidney function
Estimated creatinine clearance (eCrCl) ≥ 40 mL/min using Cockcroft-Gault formula
Liver function
ALT and AST ≤ 3 × ULN; patients with liver metastasis ≤ 5 × ULN; total bilirubin ≤ 2 mg/dL (≤ 3 mg/dL for Gilbert's syndrome)
Cardiac function
LVEF ≥ 45%; NYHA functional classification ≤ Class 1; patients ≥ 60 years with cardiac history require stress test; irreversible wall movement abnormalities excluded
Patients must have the following hematologic parameters: ANC ≥ 1000/mm3, Hemoglobin ≥ 9.0 g/dL, Platelet ≥ 100,000/mm3. Patients must have adequate organ function: ALT and AST ≤ 3 × ULN; patients with liver metastasis ≤ 5 × ULN; eCrCl ≥ 40 mL/min; total bilirubin ≤ 2 mg/dL (≤ 3 mg/dL for Gilbert's syndrome). LVEF <45% or NYHA > Class 1 excluded.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Westchester · Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05607095 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior organ allograft or prior cell transfer therapy that included a non-myeloablative or myeloablative chemotherapy regimen disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages